


# Selected Innovative Medicines in Development as of April 15, 2025



# Oncology (1 of 3)

**DARZALEX (daratumumab)**  
Smoldering Multiple Myeloma (AQUILA)

**IMBRUVICA (ibrutinib)**  
Frontline Mantle Cell Lymphoma (Triangle)

**TAR-200 (RIS/gemcitabine plus cetrelimab)**  
Non Muscle Invasive Bladder Cancer (SunRISe-1)

**CARVYKTI (Ciltacabtagene autoleucel)**  
Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

**JNJ-1900 (NBTXR3)**  
Head and Neck Cancer

**TALVEY + TECVAYLI**  
Relapsed Refractory Multiple Myeloma CD38 exposed (MonumentAL-6)

**TALVEY (talquetamab)**  
TIE NDMM in combination with DR (MajesTEC-7)

**TAR-210 (RIS/erdafitinib)**  
Intravesical Delivery System for Localized Bladder Cancer (MoonRISe-1)

**DARZALEX (daratumumab)**  
Frontline multiple myeloma transplant ineligible (CEPHEUS)

**RYBREVANT (amivantamab)**  
Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

**AKEEGA (niraparib/abiraterone)**  
M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

**ERLEADA (apalutamide)**  
Localized Prostate Cancer (ATLAS)

**RYBREVANT (amivantamab)**  
Colorectal Cancer (ORIGAMI-2)

**TALVEY (talquetamab)**  
Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumentAL-3)

**TAR-200 (RIS/gemcitabine plus cetrelimab)**  
Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

**TECVAYLI (teclistamab)**  
Multiple Myeloma 1-3PLs (MajesTEC-3)

**IMBRUVICA (ibrutinib)**  
Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)

**RYBREVANT (amivantamab)**  
Subcutaneous (PALOMA-3)

**CARVYKTI (Ciltacabtagene autoleucel)**  
Frontline Multiple Myeloma TNI (CARTITUDE-5)

**ERLEADA (apalutamide)**  
High Risk Prostate Cancer (PROTEUS)

**RYBREVANT (amivantamab)**  
Colorectal Cancer 2L (ORIGAMI-3)

**TALVEY (talquetamab)**  
Relapsed Refractory Multiple Myeloma CD38 exposed (MonumentAL-6)

**TAR-200 (RIS/gemcitabine plus cetrelimab)**  
High Risk Non Muscle Invasive Bladder Cancer BGC Experienced (SunRISe-5)

**TECVAYLI (teclistamab)**  
TE NDMM maintenance (MajesTEC-4)

## Oncology (2 of 3)

### **TECVAYLI (teclistamab)**

TIE NDMM in combination with DR (MajesTEC-7)

### **JNJ-0683 (ARX788)**

Breast Cancer

### **JNJ-0387**

Solid Tumors

### **JNJ-2421**

Solid Tumor Targeted Therapy

### **JNJ-3413**

Lymphoma

### **JNJ-4681**

Hematological Malignancies

### **JNJ-6420**

Prostate Cancer

### **JNJ-8377**

Lymphoma

### **TECVAYLI (teclistamab)**

Relapsed Refractory Multiple Myeloma CD38 exposed  
(MajesTEC-9)

### **JNJ-1900 (NBTXR3)**

Lung Cancer

### **JNJ-0631 (ARX305)**

Renal Cancer

### **JNJ-2638**

Gastrointestinal Cancer

### **JNJ-4496**

Hematological Malignancies

### **JNJ-4916**

Lung Cancer

### **JNJ-8177 (ARX517)**

Prostate Cancer

### **JNJ-8543**

Hematological Malignancies

### **bleximenib**

Relapsed Refractory Acute Myeloid Leukemia (ALE1001)

### **TALVEY + TECVAYLI**

Relapsed Refractory Multiple Myeloma (RedirectT-1)

### **JNJ-1493**

Hematological Malignancies

### **JNJ-2761**

Multiple Myeloma

### **JNJ-4680**

Lung Cancer

### **JNJ-5322**

Multiple Myeloma

### **JNJ-8343**

Prostate Cancer

### **JNJ-9401**

Prostate Cancer

## Oncology (3 of 3)

---

**JNJ-9530**

Hematological Malignancies

**JNJ-9892**

Hematological Malignancies

**JNJ-9968**

Hematological Malignancies

# Immunology (1 of 2)

**SIMPONI (golimumab)**  
Pediatric Ulcerative Colitis (PURSUIT 2)

**TREMFYA (guselkumab)**  
Crohn's Disease (GALAXI)

**TREMFYA (guselkumab)**  
Crohn's Disease Subcutaneous Induction (GRAVITI)

**icotrokinra**  
Psoriasis (ICONIC)

**nipocalimab**  
Sjogren's Disease

**STELARA (ustekinumab)**  
Pediatric Ulcerative Colitis (UNIFI JR)

**TREMFYA (guselkumab)**  
Pediatric Ulcerative Colitis (QUASAR JR)

**JNJ-4804 Co-antibody Therapy**  
Psoriatic Arthritis

**STELARA (ustekinumab)**  
Pediatric Crohn's Disease (UNITI JR)

**TREMFYA (guselkumab)**  
Pediatric Psoriasis (PROTOSTAR)

**TREMFYA (guselkumab)**  
Ulcerative Colitis Subcutaneous Induction (ASTRO)

**icotrokinra**  
Psoriatic Arthritis

**nipocalimab**  
Hemolytic Disease of the Fetus and Newborn (AZALEA)

**TREMFYA (guselkumab)**  
Psoriatic Arthritis Structural Damage (APEX)

**icotrokinra**  
Ulcerative Colitis

**JNJ-4804 Co-antibody Therapy**  
Crohn's Disease

**STELARA (ustekinumab)**  
Pediatric Juvenile Psoriatic Arthritis

**TREMFYA (guselkumab)**  
Ulcerative Colitis (QUASAR)

**TREMFYA (guselkumab)**  
Pediatric Juvenile Psoriatic Arthritis

**nipocalimab**  
Warm Autoimmune Hemolytic Anemia (ENERGY)

**nipocalimab**  
Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA)

**TREMFYA (guselkumab)**  
Pediatric Crohn's Disease (MACARONI-23)

**JNJ-4804 Co-antibody Therapy**  
Ulcerative Colitis

**JNJ-5939**  
Atopic Dermatitis

## **nipocalimab Combination Therapy**

Rheumatoid Arthritis

## **JNJ-5108**

Immunological Diseases

## **nipocalimab**

Systemic Lupus Erythematosus

## **JNJ-7528**

Atopic Dermatitis

## **nipocalimab**

Idiopathic Inflammatory Myopathy

# Neuroscience

---

## **CAPLYTA (lumateperone)**

Adjunctive Treatment for Major Depressive Disorder

## **CAPLYTA (lumateperone)**

Bipolar Mania

## **RPGR Gene Therapy**

Retinitis Pigmentosa (LUMEOS)

## **ITI-1284**

Alzheimer's Disease-Related Psychosis

## **JNJ-2056 (tau active immunotherapy) \***

Alzheimer's Disease (RETAIN)

## **posdinemab**

Alzheimer's Disease (AUTONOMY)

## **nipocalimab**

Generalized Myasthenia Gravis (Vivacity MG3)

## **CAPLYTA (lumateperone)**

Pediatric Psychiatric Indications

## **seltorexant**

Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms (OARS)

## **ITI-1284**

Alzheimer's Disease-Related Agitation

## **JNJ-5120**

Major Depressive Disorder

## **SPRAVATO (esketamine)**

Major Depressive Disorder with Suicidal Ideation  
Pediatrics

## **SPRAVATO (esketamine)**

Treatment Resistant Depression monotherapy (TRD4005)

## **nipocalimab**

Chronic Inflammatory Demyelinating Polyneuropathy (ARISE)

## **ITI-1284**

Generalized Anxiety Disorder

## **JNJ-1887 sCD59**

Geographic Atrophy

## **nipocalimab**

Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)

## Select Other Areas

### CABENUVA

HIV Adolescents

### milvexian (Factor Xla)

Secondary Stroke Prevention

### SIRTURO

Leprosy

### OPSUMIT (macitentan)

Pediatric Pulmonary Arterial Hypertension (TOMORROW)

### milvexian (Factor Xla)

Acute Coronary Syndrome

### UPTRAVI (selexipag)

Pediatric Pulmonary Arterial Hypertension (SALTO)

### macitentan

Pulmonary Arterial Hypertension 75mg (UNISUS)

### milvexian (Factor Xla)

Atrial Fibrillation

### SIRTURO

Tuberculosis Long Acting

\*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of April 15, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. \*AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; AAV-RPGR: UCL Business Plc; JNJ-1887: Hemera Biosciences; Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; REMICADE and SIMPONI/SIMPONIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Vaccine: AC Immune SA; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; DARZALEX and DARZALEX FASPRO: Genmab A/S; ERLEADA: Regents of California and Memorial Sloan Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); CD20-directed autologous CAR-Ts: Cellular Biomedicine Group, Inc. (CBMG); muscarinic M1 receptor antagonist: Pipeline Therapeutics; NBTXR3: Nanobiotix; A2a Receptor Antagonist: AdoRx Therapeutics Limited